Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12994493 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL1737899 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL13227674 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL30433831 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL30434660 | 0.95 | MDM2 (0.52) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL28625947 | 0.95 | MDM2 (0.52) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL28625949 | 0.95 | MDM2 (0.52) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL17991594 | 0.93 | MDM2 (0.54) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL29401153 | 0.93 | MDM2 (0.54) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL30468161 | 0.93 | SIRT2 (0.55) | MDM4TP53MDM2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | disclosed |
| EP-4612314-A2 | DNA CATALYST COMPOSITIONS AND METHODS OF DETECTION USING SAME | Northern Illinois Research Foundation (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | Bicyclerd Limited (GB) | 2025-08-14 | — | — | US | disclosed |
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | BICYCLETX LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| US-20250213705-A1 | PSMA TARGETING LIGANDS AND METHODS OF USE | BRIGHT PEAK THERAPEUTICS AG (CH) | 2025-07-03 | — | — | US | disclosed |
| US-12318454-B2 | Bicyclic peptide ligands specific for MT1-MMP | Bicyclerd Limited (GB) | 2025-06-03 | — | — | US | disclosed |
| WO-2025041103-A1 | PSMA TARGETING LIGANDS AND METHODS OF USE | BRIGHT PEAK THERAPEUTICS AG (CH) | 2025-02-27 | — | — | WO | disclosed |
| CN-119431497-A | Photosensitizer chimera targeting PD-L1 protein and preparation method and application thereof | 北京大学 | 2025-02-14 | — | — | CN | disclosed |
| WO-2025026029-A1 | PHOTOSENSITIZER CHIMERA TARGETING PD-L1 PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京大学 | 2025-02-06 | — | — | WO | disclosed |
| EP-3452096-B1 | BICYCLIC PEPTIDE-TOXIN CONJUGATES SPECIFIC FOR MT1-MMP | BICYCLERD LTD (GB) | 2025-01-29 | — | — | EP | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-114945579-A | Heme derivatives, their preparation and use | 吉林省澳宇生物科技有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220229066-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | INDI MOLECULAR, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | INDI MOLECULAR, INC. | 2022-07-07 | — | — | US | disclosed |
| WO-2022107134-A1 | EXTREMELY FAST SOLID PHASE SYNTHESIS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022082312-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022082006-A1 | BINDING ASSAYS INVOLVING A PLURALITY OF SYNTHETIC COMPOUNDS, TARGETS, AND COUNTER TARGETS | SRI INTERNATIONAL (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022064052-A1 | PEPTIDIC CONJUGATES OF SN38 USEFUL IN THE TREATMENT OF CANCER | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| WO-2022026629-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220229066-A1 | COMPOSITIONS, IMAGING, AND THERAPEUTIC METHODS TARGETING FOLATE RECEPTOR 1 (FOLR1) | FOLR1, FOLR2, FOLH1 | MDM4 3743/4885TP53 1046/4885MDM2 2259/4885 |
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | MMP11, MMP3, ANPEP | MDM4 3415/4885TP53 3318/4885MDM2 2867/4885 |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | MMEL1, MMP3, TIMP3 | MDM4 2089/4885TP53 826/4885MDM2 1933/4885 |
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | MDM4 3817/4885TP53 1733/4885MDM2 3597/4885 |
| US-20250213705-A1 | PSMA TARGETING LIGANDS AND METHODS OF USE | FOLH1, KLK3, PSMA2 | MDM4 1652/4885TP53 175/4885MDM2 2036/4885 |
| US-12318454-B2 | Bicyclic peptide ligands specific for MT1-MMP | MMEL1, MMP3, TIMP3 | MDM4 2089/4885TP53 826/4885MDM2 1933/4885 |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | TP53, BAX, RNASE1 | MDM4 1793/4885TP53 1/4885MDM2 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.